BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors Of The Following Investigations: Centerspace (NYSE CSR), Fulcrum Therapeutics, Inc. (Nasdaq FULC), Weave Communications, Inc. (NYSE WEAV), Bio-Techne Corporation (Nasdaq TECH)
Centerspace (NYSE – CSR)
Under the terms of the Merger Agreement, Centerspace will be acquired by Independence Realty Trust, Inc. (NYSE - IRT) in an all-stock transaction whereby Centerspace shareholders will receive 3.800 shares of IRT common stock for each share of Centerspace common stock owned. Holders of common units in Centerspace's operating partnership will receive 3.800 common units in IRT's operating partnership. Upon closing, IRT stockholders will own approximately 78% and Centerspace shareholders will own approximately 22% of the combined company's equity on a fully diluted basis, excluding preferred units. The investigation concerns whether the Centerspace Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at .
Fulcrum Therapeutics, Inc. (Nasdaq – FULC)
Under the terms of the Merger Agreement, Fulcrum Therapeutics will be acquired by Slate Medicines, Inc. Fulcrum stockholders are expected to own 5.0% of the combined company and Slate stockholders are expected to own 95.0% of the combined company. The investigation concerns whether the Fulcrum Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at .
Weave Communications, Inc. (NYSE – WEAV)
Under the terms of the Merger Agreement, Weave Communications will be acquired by Francisco Partners for $7.40 per share in cash in a deal with an aggregate equity valuation of approximately $650 Million. The investigation concerns whether the Weave Communications Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at .
Bio-Techne Corporation (Nasdaq – TECH)
Under the terms of the Merger Agreement, Bio-Techne Corporation will be acquired by Merck KGaA for $73.00 per share in cash, representing a total enterprise value of approximately $11.3 billion. The investigation concerns whether the Bio-Techne Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at .
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment